Dr Jolyon Martin, co-Founder and Head of Business Development at animal health start-up, PetMedix Ltd, has been named in the Forbes 30 under 30 Europe List for Science and Healthcare 2021.
Boehringer Ingelheim has entered into a partnership with PetMedix. Strengthening partnerships to accelerate innovation and growth is now one of the key elements of Boehringer Ingelheim’s refocused strategy.
PetMedix announces today that it has raised an equity investment from Cambridge Innovation Capital (Cambridge, UK) that will be used to advance its ground-breaking antibody technology platform seeking to bring innovative medicines to companion pets.
PetMedix now has a new home in 12,000 square feet of brand-new laboratory and office space in BioMed Realty’s latest addition to the Babraham Research
PetMedix has been voted best start-up in the global Animal Pharm Awards. The UK-based start-up is developing a new tier of monoclonal antibody therapy for the animal health market. Situated in the heart of the Cambridge biotechnology cluster, 2020 will see the company take up residence in the new Babraham Campus later in the year.
PetMedix is developing cutting-edge monoclonal antibody technology with the potential to transform a wide range of veterinary treatment options for companion animals. Founded by scientists
Scientists and technicians from around the world are gathering in Prague from June 10-13 2019 for the FELASA conference, and PetMedix’s head of experimental animals will be there, giving real practical examples of how to reduce harm and improve animal welfare.
Building on the momentum from the recent announcement of an £8M Series A investment, PetMedix is delighted that Fabian Kausche, Dr.med.vet., M.S. will be joining
PetMedix is applying 30 years of antibody research and the scientific work of two of its founders, Professor Allan Bradley FRS and Dr Jolyon Martin, to develop new pet therapeutics against a wide range of diseases. Led by founder and CEO, Dr Tom Weaver, PetMedix has recently raised £8 million in Series A funding and will use this to establish operations, grow the team, continue to build the platforms, and begin drug discovery. The investment was led by Digitalis Ventures (NYC) with Parkwalk Advisors (London) as their syndicate partner.